TNBIOTCGrain Mill ProductsFiscal year ends December 31
Tanke Biosciences Corp
Financials through Q3 FY2013, quarter ended Sep 30, 2013Last filing: 10-Q on Nov 14, 2013
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $399.72K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2009 to 2012
Gross margin
34.8%
Operating margin
15.9%
Net margin
-0.7%
Growth rates
Compound annual growth to fiscal 2012
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.8% | – | – | – | |
| Gross profit | +13.4% | – | – | – | |
| Operating income | +160.6% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2009 | FY2009 | FY2012 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -1.3% | |
| Return on assets | – | – | -0.8% | |
| Current ratio | – | – | 1.85 | |
| Debt to equity | – | – | 0.13 | |
| Net debt to EBITDA | – | – | -0.79× | |
| Interest coverage | – | – | 3.1× | |
| Inventory turnover | – | – | 14.3× | |
| Capex to revenue | – | – | 3.0% | |
| Diluted shares | – | – | 13M |
Cash use needs five years of cash flow figures
Tanke Biosciences does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-0.7%
×Asset turnover1.06×
×Equity multiplier1.70×
=Return on equity, FY2012-1.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2012 | -0.7% | 1.06× | 1.70× | -1.3% |
| FY2011 | -13.2% | 1.25× | 1.59× | -26.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2012 against fiscal 2011
1of 9 tests passed in fiscal 2012. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$210.25K
- Cash generatingOperating cash flow above zero-$1.18M
- Return on assets improvedROA up on the prior year-23.6% → -0.8%
- Earnings backed by cashOperating cash flow above net income-$1.18M vs -$210.25K
- Less leverageLong-term debt to assets fell2.5% → 2.7%
- Better liquidityCurrent ratio rose5.33 → 1.85
- No dilutionShare count did not rise13M → 13M
- Gross margin improvedGross margin up on the prior year36.80% → 34.82%
- More efficientAsset turnover rose1.80 → 1.15